financetom
Business
financetom
/
Business
/
Rent The Runway Q1 Subscriber Growth Returns, Eyes Double-Digit Increase In FY25
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rent The Runway Q1 Subscriber Growth Returns, Eyes Double-Digit Increase In FY25
Jun 6, 2025 4:51 AM

Rent The Runway, Inc. ( RENT ) shares are trading higher premarket on Friday after the company reported first-quarter financial results on Thursday after market close.

The rent and subscription based e-commerce platform clocked GAAP earnings per share of $6.58 loss, beating the street view of $8.35 loss.

Quarterly sales of $69.6 million fell 7.2% year over year (Y/Y) but beat the analyst consensus estimate of $68.7 million.

Also Read: Trump Announces China Trade Talks, Tesla Stock Slumps: What’s Driving Markets Thursday?

Gross profit was $21.9 million, down 22.9% Y/Y. The gross margin fell to 31.5% compared to 37.9% in the year-ago period.

Adjusted EBITDA for the quarter was a loss of $1.3 million versus a profit of $6.5 million in the year-ago period. Adjusted EBITDA loss margin was negative 1.9%, compared to 8.7% in the first quarter of fiscal year 2024.

Active Subscribers stood at 147,157, marking a 1% increase year over year, and total subscribers at period-end stood at 182,209, down 2% year over year in the quarter.

Sid Thacker, Chief Financial Officer of Rent the Runway ( RENT ) said, “We are happy with the sequential growth in ending active subscribers and continue to expect double digit growth in ending active subscribers for fiscal year 2025.”

The company exited the quarter with cash and equivalents worth $70.4 million and long-term debt of $340.6 million.

Outlook: For the second quarter of fiscal 2025, Rent the Runway ( RENT ) expects revenue of $76 million to $80 million (estimate: $75.50 million) and adjusted EBITDA margin of between -2% and +2%.

The company continues to project 2025 free cash outflow of $30 million to $40 million for the year.

It is noteworthy that RENT stock is down 20.71% year-to-date and has a short interest of 9.63% of float.

Price Action: RENT shares are trading higher by 20.92% to $8.15 premarket at last check Friday.

Read Next:

Top 3 Risk Off Stocks That Could Blast Off This Month

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Theratechnologies to Present Data Next Week Highlighting Advances in Treatment in People with HIV
Theratechnologies to Present Data Next Week Highlighting Advances in Treatment in People with HIV
Oct 9, 2024
08:01 AM EDT, 10/09/2024 (MT Newswires) -- Theratechnologies ( THTX ) on Wednesday announced three poster presentations at IDWeek 2024 taking place next week in Los Angeles. One poster presents data linking excess visceral abdominal fat (EVAF) to increased cardiovascular risk in people with HIV, while a second poster documents how use of tesamorelin, a growth hormone-releasing factor analog, to...
Stallion Uranium Signs Letter of Intent for Horse Heaven Gold and Antimony Project
Stallion Uranium Signs Letter of Intent for Horse Heaven Gold and Antimony Project
Oct 9, 2024
07:50 AM EDT, 10/09/2024 (MT Newswires) -- Stallion Uranium ( STLNF ) on Wednesday said it has entered into a binding letter of intent to grant an 80% interest in its Horse Heaven Gold and Antimony project to an arm's-length party for staged payments of $600,000 cash and $1.1 million worth of optionor shares. The optionor must also complete $5...
Hyundai to use $3 bln record India IPO proceeds for new cars, R&D
Hyundai to use $3 bln record India IPO proceeds for new cars, R&D
Oct 9, 2024
* Hyundai IPO biggest ever in India, Asia's biggest in 2024 * Company wants to expand in India; first listing outside S.Korea * Hyundai aims to make India a manufacturing hub for emerging mkts * Executive says 30% increase in production seen in 3-4 years (Adds details, comments in paragraph 7, 11, 16-17) By Dhwani Pandya MUMBAI, Oct 9 (Reuters)...
Can-Fite BioPharma Says Its Pancreatic Cancer Drug Candidate Receives US FDA Orphan Drug Designation
Can-Fite BioPharma Says Its Pancreatic Cancer Drug Candidate Receives US FDA Orphan Drug Designation
Oct 9, 2024
07:51 AM EDT, 10/09/2024 (MT Newswires) -- Can-Fite BioPharma ( CANF ) said Wednesday that its oncology drug candidate Namodenoson, whihc treats pancreatic cancer, has received Orphan Drug Designation from the US Food and Drug Administration. The company said it is now finalizing all preparatory requirements for a mid-stage trial in participants suffering from pancreatic cancer to evaluate the safety,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved